Company Intervacc AB

Equities

IVACC

SE0009607252

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Intervacc AB

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Stockholm Other stock markets 06:59:52 2024-04-30 am EDT			5-day change	1st Jan Change
4.205 ^SEK	+0.72%		+4.99%	-33.57%

Mar. 04	Intervacc AB Announces Changes in the Nomination Committee	CI
Feb. 28	Intervacc's Acting CEO Assumes Role Permanently	MT

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâs candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Number of employees: 15

SEK in Million	2021	Weight	2022	Weight	Delta
Novel Veterinary Vaccines 100.0 %	5	100.0 %	10	100.0 %	+84.77%

SEK in Million	2021	Weight	2022	Weight	Delta
Sweden 100.0 %	5	100.0 %	10	100.0 %	+84.77%

Managers	Title	Age	Since
Jonas Sohlman CEO	Chief Executive Officer	-	23-08-20
Jan Persson DFI	Director of Finance/CFO	-	20-02-05
Andrew Waller CTO	Chief Tech/Sci/R&D Officer	-	20-06-10
Patrik Hellberg CIO	Chief Investment Officer	-	-
Tim Wood LAW	General Counsel	-	18-07-31
Andreas Johansson PRN	Corporate Officer/Principal	45	10-12-31

Members of the board	Title	Age	Since
Boel Sundvall BRD	Director/Board Member	65	22-12-31
Björn Magnus Sjöstrand CHM	Chairman	56	-
Edwin Torr BRD	Director/Board Member	63	-
Bengt Stefan Ståhl BRD	Director/Board Member	63	08-12-31
Bengt Guss FOU	Founder	66	00-12-31
Niels Holcke BRD	Director/Board Member	-	19-12-31
Michela de Carli BRD	Director/Board Member	-	21-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	75,736,264	59,198,500 ( 78.16 %)	0	78.16 %

Name	Equities	%	Valuation
Swedbank Robur Fonder AB 6.773 %	5,129,802	6.773 %	2 M kr
Handelsbanken Fonder AB 6.029 %	4,565,935	6.029 %	2 M kr
Fjärde AP-fonden 4.951 %	3,750,000	4.951 %	1 M kr
Björn Magnus Sjöstrand 2.478 %	1,876,862	2.478 %	649 451 kr
H Bjorklund 2.010 %	1,522,647	2.010 %	526 882 kr
M Lundberg 2.009 %	1,521,648	2.009 %	526 536 kr
Aktia Bank Plc (Investment Management) 1.525 %	1,155,000	1.525 %	399 665 kr
Aktia Fondbolag Ab 1.525 %	1,155,000	1.525 %	399 665 kr
Kenneth Janzon 1.514 %	1,146,500	1.514 %	396 723 kr
Nordea Investment Management AB 1.496 %	1,132,944	1.496 %	392 033 kr

Intervacc AB

Västertorpsvägen 135 Hägersten

129 44, Stockholm

+46 8 12 01 06 00

http://www.intervacc.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
INTERVACC AB	-33.57%	28.99M
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-15.84%	21.4B
GENMAB A/S	-9.21%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-14.65%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.83B
SAREPTA THERAPEUTICS, INC.	+31.35%	11.97B

Bio Therapeutic Drugs